| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/20/2001 | CA2402427A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 09/20/2001 | CA2402413A1 Compositions and methods for affecting osteogenesis |
| 09/20/2001 | CA2402259A1 Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections |
| 09/20/2001 | CA2402250A1 Immunomodulatory polynucleotide sequences for use in suppressing hepatitis virus infection |
| 09/20/2001 | CA2402248A1 Polypeptides and nucleic acids encoding same |
| 09/20/2001 | CA2402122A1 D-enantiomer of dfmo and methods of use therefor |
| 09/20/2001 | CA2402041A1 Antisense oligonucleotides of the human chk1 gene and uses thereof |
| 09/20/2001 | CA2401448A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 09/20/2001 | CA2400370A1 Nucleoside compounds and uses thereof |
| 09/20/2001 | CA2400106A1 Antibodies to human cd154 |
| 09/20/2001 | CA2400043A1 Antiviral prodrugs |
| 09/20/2001 | CA2373110A1 Production of chimeric capsid vectors |
| 09/19/2001 | EP1134290A2 Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| 09/19/2001 | EP1134215A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases |
| 09/19/2001 | EP1133994A1 A method for reversing the immunosuppressive effects of the Melanoma Inhibitory Activity "MIA" |
| 09/19/2001 | EP1133992A1 Novel pharmacological activities of curcuma longa extracts |
| 09/19/2001 | EP1133988A1 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 09/19/2001 | EP1133986A1 Use of deramciclane for the treatment of anxiety and depression |
| 09/19/2001 | EP1133699A1 Prevention and treatment of amyloid-associated disorders |
| 09/19/2001 | EP1133552A2 Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
| 09/19/2001 | EP1133519A2 Functional antagonists of hedgehog activity |
| 09/19/2001 | EP1133512A2 Benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133510A2 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133508A2 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133507A2 Benzyllactobionamides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133506A2 Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133494A1 8-azabicyclo 3.2.1]oct-2-ene and -octane derivatives |
| 09/19/2001 | EP1133491A1 Novel benzofurane derivatives, preparation method, use as medicines and pharmaceutical compositions containing same |
| 09/19/2001 | EP1133488A1 Propanoic acid derivatives as integrin inhibitors |
| 09/19/2001 | EP1133487A1 Scavenger compounds |
| 09/19/2001 | EP1133483A1 Il-5 inhibiting 6-azauracil derivatives |
| 09/19/2001 | EP1133481A1 Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors |
| 09/19/2001 | EP1133480A1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors |
| 09/19/2001 | EP1133479A1 Quinoline and quinoxaline compounds |
| 09/19/2001 | EP1133478A1 Novel acylguanidine derivatives, method for preparing same, application as medicines and pharmaceutical compositions containing them |
| 09/19/2001 | EP1133477A1 Substituted benzimidazoles and their use as parp inhibitors |
| 09/19/2001 | EP1133475A1 Substituted benzo de]isoquinoline-1,3-diones |
| 09/19/2001 | EP1133474A1 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators |
| 09/19/2001 | EP1133467A1 Ion channel modulating agents |
| 09/19/2001 | EP1133317A1 Transport system conjugate |
| 09/19/2001 | EP1133311A2 INFLUENCING OF ANGIGENESIS USING CD66a |
| 09/19/2001 | EP1133303A2 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133292A1 A new pharmaceutical composition |
| 09/19/2001 | EP1133230A1 Dosage formulations for acetylcholinesterase inhibitors |
| 09/19/2001 | EP0948522A4 Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines |
| 09/19/2001 | EP0923529B1 Substitute 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors |
| 09/19/2001 | EP0880522B1 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-4-ONE DERIVATIVES AMPA AND NMDA RECEPTORS ANTAGONISTS, PREPARATION THEREOF, INTERMEDIATES THEREOF AND DRUGS CONTAINING SAME |
| 09/19/2001 | EP0869954B1 Heterocyclic compounds for use in the treatment of neurogenic inflammation |
| 09/19/2001 | EP0853616B1 Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
| 09/19/2001 | EP0772630B1 Streptogramine derivatives, preparation of same and pharmaceutical compositions containing same |
| 09/19/2001 | EP0770077B1 Process for the preparation of 2-(1-azabicyclo(2.2.2)oct-3-yl) -2,4,5,6-tetrahydro-1h-benz(de)isoquinolin-1-one and intermediate product |
| 09/19/2001 | EP0675712B1 Reduction of hair growth employing sulfhydryl reactive compounds |
| 09/19/2001 | EP0640099B1 Peptides having tachykinin antagonist activity |
| 09/19/2001 | EP0612244B1 Endothelin receptor antagonists |
| 09/19/2001 | EP0594667B1 Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| 09/19/2001 | CN1313863A Inhibitors of urokinase and blood vessel fomation |
| 09/19/2001 | CN1313861A 2-(purin-9-YL)-tetrahydrofuran-3,4-diolderivatives |
| 09/19/2001 | CN1313846A C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cystenine proteases |
| 09/19/2001 | CN1313772A Peptide antagonists of zonulin and methods for use of same |
| 09/19/2001 | CN1313767A Carbamate and urea compositions and neurotrophic uses |
| 09/19/2001 | CN1313766A DNA-cleaving antitumor agents |
| 09/19/2001 | CN1313765A Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents |
| 09/19/2001 | CN1313756A Oral liquid mucoadhesive compositions |
| 09/19/2001 | CN1313754A Oral liquid mucoadhesive compositions |
| 09/19/2001 | CN1313338A Polypeptide motif bound with human CD95 and its polypeptide |
| 09/19/2001 | CN1313280A Benzheterocyclic derivatives |
| 09/19/2001 | CN1313120A Face-beautifying buccal lozenge and its preparing process |
| 09/19/2001 | CN1313107A Chinese medicine for prepventing and treating iatrogenic hypercortisonism |
| 09/19/2001 | CN1071329C Aryl glycinamide derivatives, methods of producing these substances and pharmaceutical compositions containing such compounds |
| 09/19/2001 | CN1071328C Arginine angalogues having nitric oxide synthase inhibitor activity |
| 09/19/2001 | CN1071327C Denzothiazine dioxides as endothelin antagonists |
| 09/19/2001 | CN1071325C Thiol derivatives with metallopeptidase inhibitory activity |
| 09/19/2001 | CN1071318C Ortho-substd. benzoyl guanidines, their preparing process and use as medicine and diagnostic reagent, and medicine contg. same |
| 09/18/2001 | US6291672 Human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them |
| 09/18/2001 | US6291657 N-butyldeoxygalactonojirimycin; suppression of glycolipid biosynthesis; microbiocides; treatment of gaucher's disease |
| 09/18/2001 | US6291643 Apaf-1 an activator of caspase-3 |
| 09/18/2001 | US6291642 Mammalian cell cycle protein |
| 09/18/2001 | US6291530 Aryl-substituted acrylamides with Leukotriene B4 (LTB-4) receptor antagonist activity |
| 09/18/2001 | US6291520 Hydroxamic acid and N-hydroxyurea derivatives and their use |
| 09/18/2001 | US6291516 Contacting the cell with a composition including at least one cyclic amp agonist. |
| 09/18/2001 | US6291507 Chemical compounds |
| 09/18/2001 | US6291503 β-phenylalanine derivatives as integrin antagonists |
| 09/18/2001 | US6291499 2-cyclohexyl benzimidazole NMDA/NR2B antagonists |
| 09/18/2001 | US6291489 Process for substituted pyridines |
| 09/18/2001 | US6291488 Administering 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone and 1-(4-chlorophenyl)-5-isopropylbiguanide hydrochloride in a ratio of 1:1 to 3:1. |
| 09/18/2001 | US6291485 Treatment of post-ptca restenosis |
| 09/18/2001 | US6291466 Cholinergic agents in the treatment of presbyopia |
| 09/18/2001 | US6291465 Biphenyl derivatives |
| 09/18/2001 | US6291464 Aminopiperazine derivatives |
| 09/18/2001 | US6291460 Treatment of anxiety; treatment and/or prevention of convulsions |
| 09/18/2001 | US6291458 Morpholinobenzamide salts |
| 09/18/2001 | US6291455 Producing an antiangiogenic and/or vascular permeability reducing effect |
| 09/18/2001 | US6291450 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use |
| 09/18/2001 | US6291440 Iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency |
| 09/18/2001 | US6291211 Expressing heterologous polypeptides in cells; incubate cells with expression vectors, transform cells, express heterologous polypeptide |
| 09/18/2001 | US6291206 BMP receptor proteins |
| 09/18/2001 | US6291195 Generating ligands which bind preferential human receptors; incubate cells expressing preferential binding protein with modulator, detect adjustment in binding activity |
| 09/18/2001 | US6290985 By chewing the gum, the medicament or agent is released from the product. |
| 09/18/2001 | US6290957 Anti-IgE antibodies and method of improving polypeptides |
| 09/18/2001 | US6290952 Method of dephosphorylating an endotoxin in vivo with alkaline phosphatase |